If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
312.00    0.00 (0.00%)
Bid:
310.00
Ask:
314.00
Spread: 4.00 (1.29%)
Market Cap: £39.59m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Director/PDMR Shareholding

14 Sep 2007 13:15

BrainJuicer Group PLC14 September 2007 BrainJuicer Group PLC ("BrainJuicer" or "the Company") Directors Dealings BrainJuicer Group PLC, (AIM: BJU), a leading international online marketresearch agency, was today informed that Ken Ford, Non-Executive Chairman, hastoday purchased 10,000 Ordinary Shares of 1p each in the Company ("OrdinaryShares") at a price of 202p per Ordinary Share. Following this transaction, Mr.Ford is interested in 10,000 Ordinary Shares, representing 0.08% of the totalissued share capital of the Company. - Ends - For further information, please contact:BrainJuicer plcJohn Kearon, Chief Executive Officer Tel: +44 (0)20 7043 1000 www.brainjuicer.com Landsbanki Securities (UK) LimitedFred Walsh / Simon Brown Tel: +44 (0)20 7426 9000 www.landsbanki.co.uk Media enquiries:Abchurch CommunicationsHeather Salmond / Joanne Shears Tel: +44 (0) 20 7398 7700joanne.shears@abchurch-group.com www.abchurch-group.com Notes to Editors: BrainJuicer carries out quantitative online research using innovative, bespokesoftware to produce insightful market research for large, multinationalcompanies, including 10 of the world's top 50 companies (FT 500 September 2006). BrainJuicer operates in a growing sector of the US$25bn global research market,namely quantitative online research. BrainJuicer's main competitors are largetraditional market research providers who have dominated the market for off-linemarket research, such as AC Nielsen, Millward Brown, Research International andTaylor Nelson Sofres. Whilst the largest traditional research companies have developed their ownonline capability, BrainJuicer has a number of key attributes which havecontributed to it achieving rapid growth and winning contracts with prestigiousclients, including: β€’ Research platform that delivers greater diagnostic insight. BrainJuicer hasdeveloped tools and award-winning techniques that enable it to provide a greaterlevel of diagnostic insight into quantitative market research. These techniquesenable clients to enhance their understanding of consumer preference and helpthem make decisions on the best way to develop their products and services. β€’ Speed. BrainJuicer's automated research techniques enable it to conductcomplicated studies very quickly. BrainJuicer's rapid deployment and resultsproduction, even on multi-country studies, provide clients with a speed tomarket advantage in the development of new products and services. β€’ A scaleable online-only business model. Unlike the traditional researchcompanies who maintain both on and offline data collection capabilities,BrainJuicer is able to focus on operating a scaleable online-only businessmodel. To date the Group has conducted projects in over 50 countries and more than 30languages and has established offices in the UK, the Netherlands and the US. The Group's revenues come from full service market research work, and from itsonline Juicy Brains Panel in the UK. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Oct 20247:00 amRNSTrading Update
25th Sep 20245:15 pmRNSResult of AGM & Notice of H1 Trading Update
12th Aug 20244:15 pmRNSAnnual Report and Notice of AGM
18th Jul 20247:00 amRNSDirector/PDMR Shareholding
12th Jul 20247:00 amRNSFinal Results (correction)
12th Jul 20247:00 amRNSTrading Update
3rd Jul 20247:00 amRNSFinal Results
28th Jun 20243:27 pmRNSUpdate re Director Disclosure
27th Jun 20246:00 pmRNSNotice of Final Results and IMC presentation
24th Jun 20242:52 pmRNSHolding(s) in Company
30th May 20241:04 pmRNSCorrection of Total Voting Rights
28th May 20245:15 pmRNSExercise of Options and Total Voting Rights
28th May 20242:00 pmRNSHolding(s) in Company
24th May 20244:30 pmRNSHolding(s) in Company
24th May 20243:00 pmRNSHolding(s) in Company
24th May 202411:15 amRNSHolding(s) in Company
24th May 202410:30 amRNSHolding(s) in Company
16th Apr 20247:00 amRNSTrading Update
24th Jan 20247:00 amRNSTrading Update
12th Dec 202312:51 pmRNSPresentation via Investor Meet Company
6th Dec 20237:00 amRNSChange of Auditor
6th Dec 20237:00 amRNSInterim Results
24th Oct 20237:00 amRNSTrading Update
27th Sep 20236:00 pmRNSResult of AGM
27th Sep 20237:00 amRNSTrading Update
31st Aug 20237:00 amRNSAnnual Report and Notice of AGM
1st Aug 20237:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 MAR 2023
31st Jul 20232:00 pmRNSPreliminary Results Presentation
13th Jul 20237:30 amRNSTrading update
30th Jun 20239:00 amRNSResolution of Complaint for Trademark Infringement
28th Jun 202311:00 amRNSHolding(s) in Company
3rd May 20233:15 pmRNSFurther re Result of General Meeting
21st Apr 202311:56 amRNSResult of General Meeting
13th Apr 20237:00 amRNSFurther re Requisitioned General Meeting
12th Apr 20237:00 amRNSTrading Update
5th Apr 202310:45 amRNSNotice of Trading Update
24th Mar 20234:00 pmRNSPosting of Circular and Notice of Requisitioned GM
24th Mar 20237:00 amRNSPosting of Circular and Notice of Requisitioned GM
7th Mar 20237:30 amRNSReceipt of Requisition Notice
28th Feb 202312:50 pmRNSCapital Markets Day
23rd Feb 20237:00 amRNSTrading Update
14th Feb 20237:00 amRNSCapital Markets Day
13th Jan 20232:00 pmRNSDirector/PDMR Shareholding
10th Jan 202310:30 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSDirector/PDMR Shareholding
14th Dec 20224:00 pmRNSDirector/PDMR Shareholding
13th Dec 20226:25 pmRNSDirector/PDMR Shareholding
6th Dec 20224:15 pmRNSDirectorate Change
30th Nov 20227:00 amRNSInterim Results
25th Oct 20227:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.